Gilead Sciences Inc (GILD) Stock Forecast
US · Healthcare
Current price
$123.84
Market cap
$153.76B
Mean price target
$157.57
Implied upside
27.2%
Key takeaways
- Analysts rate Gilead Sciences Inc a “Buy”, with a mean price target of $157.57 — about 27.2% upside from the current $123.84, based on 28 analysts.
- GILD is trading in the middle of its 52-week range, at 35% of the $105.79–$157.29 band.
Analyst consensus
| Consensus rating | Buy |
|---|---|
| Number of analysts | 28 |
| Mean target | $157.57 |
| High target | $180.00 |
| Low target | $122.00 |
| Rating split (SB / B / H / S / SS) | 5 / 18 / 8 / 0 / 0 |
Price & trading
| Current price | $123.84 |
|---|---|
| Previous close | $125.15 |
| 52-week high | $157.29 |
| 52-week low | $105.79 |
| 50-day average | $130.88 |
| Beta | 0.33 |
See the full GILD breakdown on Luminoso
Valuation, profitability, efficiency, leverage & earnings-quality metrics — updated daily.
Start free — 2 months on usFrequently asked questions
- What is the current Gilead Sciences Inc (GILD) share price?
- Gilead Sciences Inc last traded at $123.84 with a market capitalisation of about $153.8B.
- What is the analyst price target for GILD?
- The mean analyst price target for Gilead Sciences Inc is $157.57, roughly 27.2% above the latest price. The current consensus rating is “Buy”.
- Where can I see Gilead Sciences Inc's full financial metrics?
- Luminoso tracks GILD's valuation, profitability, efficiency, leverage and earnings-quality metrics alongside analyst data — updated daily. Create a free account to explore the full breakdown.
More stocks
Browse all companies covered by Luminoso →
Last updated 25 Jun 2026.
Data is provided for informational purposes only and is not investment advice. Figures are cached and refreshed daily; they may differ from real-time quotes.